Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588106 | 0.92 | USP14 (0.45) | USP14NPY5RKDM4DF10DRD2 | |
| SCHEMBL3594724 | 0.90 | CCR2 (0.41) | CCR2DRD2 | |
| SCHEMBL3594722 | 0.90 | CCR2 (0.41) | CCR2DRD2 | |
| SCHEMBL3584031 | 0.90 | USP14 (0.42) | USP14NPY5RKDM4DF10DRD2 | |
| SCHEMBL3589762 | 0.84 | CNR1 (0.43) | — | |
| SCHEMBL15182152 | 0.84 | KMT2A (0.36) | DRD2 | |
| SCHEMBL15169813 | 0.82 | MCHR1 (0.37) | DRD2 | |
| SCHEMBL3596723 | 0.82 | TSHR (0.35) | DRD2 | |
| SCHEMBL3596729 | 0.82 | TSHR (0.35) | DRD2 | |
| SCHEMBL13168320 | 0.82 | DDR1 (0.39) | KDM4DDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | USP14 3656/4885NPY5R 244/4885SCN9A 1061/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | USP14 3656/4885NPY5R 244/4885SCN9A 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.